Quantcast

Latest H5N1 clinical trials Stories

25fee368bc94161000aefac4fdfc84f71
2009-12-26 07:05:00

Accelerated approval process used in vaccine approval The U.S. Food and Drug Administration this week approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B. People in this age group are at highest risk for seasonal influenza complications, which may result in hospitalization and death. Annual vaccination remains the best protection from influenza, particularly for people 65 and...

2009-12-21 15:13:04

One dose of vaccine may be effective to protect infants and children and reduce transmission of the H1N1 virus, according to a study in JAMA, published online today because of its public health implications. The study will appear in the January 6 print edition of the journal. Initial reports of 2009 influenza A(H1N1) infection in many countries have largely involved children, especially those attending school. Reports have also indicated high hospitalization rates of children younger than 5...

2009-12-15 08:00:00

LYON, France and SWIFTWATER, Pa., Dec. 15 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it is expanding its phase II clinical study of a vaccine against Clostridium difficile infection (CDI) into the United States. The trial started in the United Kingdom earlier this year. The incidence of CDI has increased significantly in recent years in both North America and Europe. CDI-related treatments in these two regions of the...

7c002da4103729c4eebdccee1a004240
2009-12-04 10:35:00

The European Medicines Agency announced that young children who are receiving GlaxoSmithKline's H1N1 vaccine may contract a fever after the second injection. In a statement was released Friday, and the European drug controller added that statistics pulled from GlaxoSmithKline PLC indicated a large amount of children from six months to 3 years contracted a fever after the second dose of the vaccine. Other side effects reported included muscle discomfort, sleepiness, and irritability. The...

2009-12-02 07:05:00

ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and potentially other countries. In Stage A of this...

2009-12-01 07:00:00

BEIJING, Dec. 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its fourth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for the national purchase plan. Under this purchase order, Sinovac is required to produce an additional one million doses of PANFLU.1 (TM) (15ug/0.5ml) for the Chinese central government. The delivery of...

2009-11-30 07:05:00

ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal...

6398326d01aed6b3956ff4571c196d5a1
2009-11-24 12:52:40

The WHO said on Tuesday that GlaxoSmithKline recalled a batch of swine flu vaccine in Canada after a number of severe allergic reactions surfaced, The Associated Press reported. The recall was issued after reports that one batch of the swine flu vaccine might have caused more allergic reactions than normal, according to company spokeswoman Gwenan White. White said GlaxoSmithKline advised health care professionals not to use the batch while health authorities investigate. However, the batch in...

89cdb83d08f3bae5bc694b94b65392e81
2009-11-24 06:00:00

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) on Monday voiced concerns about the sluggish vaccination rate for the H1N1 swine flu due to public skepticism over health risks and side effects. "ESCMID joins others concerned about the lack of uptake due to both public skepticism and deliberate misinformation being raised by a growing anti-vaccination movement in a number of countries," the group said in a statement. "It is feared a low uptake of the vaccine...

2009-11-16 07:00:00

ROCKVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico. An independent data and safety monitoring board has reviewed preliminary safety data from the first half of this cohort and recommended that this first stage continue as planned. The study is being...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related